Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation Report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • NHS Psychological Support
    • Confidential Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Subscribe to Search results

It was noted at Working Party meeting on the Treatment of Haemophiliacs that there was a shortfall of 3.5 million units of Factor 8 which it was agreed should be made up by commercial Factor 8.

Published on: 30 September, 2024

Professor Franklin wrote to Dr Lane registering his concern about the shortfall, which meant that the Centre might have to treat patients with commercial product who had never been exposed to it in the past.

Published on: 30 September, 2024

The West Midlands Working Party held an extraordinary meeting to discuss the implications of the use of Factor 8 concentrates in light of the death of two people with haemophilia from AIDS and a treatment policy was agreed

Published on: 30 September, 2024

Professor Bloom told the audience at a Haemophilia Society meeting that one of his patients "may have a mild form" of the syndrome.

Published on: 30 September, 2024

Professor Lee confirmed that no changes were made in the Royal Free's treatment policies until heat-treated products became available at the end of 1984

Published on: 30 September, 2024

NETR Haemophilia Working Party agreed to use heat-treated material whenever possible and to treat all new patients and those with mild haemophilia with heat-treated NHS concentrate or small pool Factor 8 concentrate if treatment with cryoprecipitate or DDAVP was not possible.

Published on: 30 September, 2024

The Royal Free's annual return for 1983 showed that commercial concentrates remained the principal treatment for Haemophilia A.

Published on: 30 September, 2024

The Royal Free's annual return for 1984 showed that commercial concentrates remained the principal treatment for Haemophilia A, although the volume of NHS concentrates increased.

Published on: 30 September, 2024

Dr Kernoff wrote to patients explaining that it would not be possible to change everybody to heat-treated products immediately. The overall objective of the Royal Free's policy was said to be to give the safest possible treatment to an individual.

Published on: 30 September, 2024

In a letter to John Watt, it was stated that Dr Ludlam planned to start an active home therapy programme for some of his haemophilic patients.

Published on: 30 September, 2024

In his witness statement, Professor Ludlam accepted that cryoprecipitate had transformed the treatment of patients with Haemophilia A and allowed most bleeds in non-inhibitor patients to be treated effectively.

Published on: 30 September, 2024

Donor blood plasma was redirected from cryoprecipitate production to concentrate manufacture.

Published on: 30 September, 2024

Professor Ludlam did not proactively raise the question of AIDS risks with patients.

Published on: 30 September, 2024

Dr Boulton wrote to Professor Ludlam, warning that the South East Scotland Blood Transfusion Centre was at the limits of production of concentrates for home therapy and indicated that Professor Ludlam may consider the necessity for buying some commercial product. Dr Boulton also encouraged Professor Ludlam to maximise use of the cryoprecipitate programme.

Published on: 30 September, 2024

At the meeting with Dr Boulton, Dr Ludlam agreed to make additional efforts to keep within the monthly allocation of concentrate from PFC, while Dr Boulton reiterated his warning that there would be need to buy more commercial Factor VIII.

Published on: 30 September, 2024

Similar concerns regarding use of Factor VIII concentrates and purchase of commercial products were raised at the meeting of the Lothian Health Board Area Executive Group.

Published on: 30 September, 2024

Dr Boulton continued to express concerns that Dr Ludlam's home therapy programme was using a large proportion of the allocation from PFC and that he may need to buy commercial Factor VIII if the usage pattern continued.

Published on: 30 September, 2024

Dr Boulton stated that Dr Ludlam was beginning to use less PFC material in favour of cryoprecipitate and that this was an encouraging trend. Edinburgh also sourced Factor VIII from Inverness and Glasgow.

Published on: 30 September, 2024

Dr Ludlam felt that he was not getting the supply of PFC material that had been agreed.

Published on: 30 September, 2024

At Edinburgh Haemophilia Centre, there was a reduction in the use of cryoprecipitate and an increase in the use of NHS concentrate, with both Factorate and Koate being used in larger quantities than before.

Published on: 30 September, 2024

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 2334
  • Page 2335
  • Page 2336
  • Page 2337
  • Current page 2338
  • Page 2339
  • Page 2340
  • Page 2341
  • Page 2342
  • …
  • Next page Next
  • Last page Last

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.